-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In the first half of 2022, affected by factors such as the adjustment of the approval policy for innovative drugs and the uncertainty of the expected value realization of biopharmaceutical companies by the capital market, the investment and financing trend in the medical and health sector has slowed down as a who.
According to the statistics of InvestGO, in the first half of 2022, there were 583 investment and financing events in the primary market, a year-on-year decrease of 47%; 30 IPO events, a year-on-year decrease of 45%; and 19 secondary market refinancing events, a year-on-year decrease of 5
However, innovative drugs and medical devices are still favored by capital, with over 300 investment and financing events in the first half of the ye.
Among them, there are 161 cases in the field of innovative drugs and 150 cases in medical devic.
In the field of innovative drugs, 34 of the 161 financing events focused on cell therapy, of which 14 were over RMB 100 milli.
In addition, there were 26 financing events in gene therapy, of which 10 were over RMB 100 milli.
It can be seen that cell therapy and gene therapy are hot tracks for innovative dru.
It is understood that cell therapy refers to the use of patient's autologous or allogeneic adult cells or stem cells, which are processed by a series of bioengineering techniques such as acquisition, isolation, culture expansion, and screening, and then returned to the patient's bo.
, Organ repair treatme.
It has great application potential in the treatment of cancer, autoimmune diseases, cardiovascular diseases and other major diseas.
In recent years, due to the resonance of multiple factors such as favorable policies and capital overweight, the cell therapy market has continued to gr.
According to Frost & Sullivan, China's cell therapy market space will increase from 3 billion yuan in 2021 to 54 billion yuan in 2030, with an average annual growth rate of 5Gene therapy is a new generation of precision therapy, which can provide new treatment concepts and means for tumors, rare diseases, chronic diseases and other intractable diseas.
As early as March 24, KPMG's "One Time Curing" Gene Therapy report pointed out that under the background that cell and gene therapy has become one of the eye-catching emerging fields in the global biotechnology field, the field of gene therapy continues to receive investo.
and large investments in biopharmaceutical compani.
Another data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from US$22 billion to US$19 billion, with an average annual compound growth rate of nearly 4
Medical devices have also attracted much attention from capit.
Among the 150 financing events in this field in the first half of the year, the average single transaction amounted to 99 million yuan, an increase of 19% over last ye.
In recent years, with the strong downstream demand, the domestic medical device industry has developed rapidly, and domestic substitution has accelerated, and the market scale has continued to expa.
A research report shows that since 2013, the market scale of China's medical device industry has continued to expa.
It is estimated that by 2022, the size of China's medical device market will reach 1,259 billion yuan, and in 2025, it will reach 1,844 billion yu.
At present, the policy side is also continuing to support the innovative development of the medical device indust.
For example, in June this year, the Shanghai Stock Exchange issued and implemented the "Guidelines for the Application of the Shanghai Stock Exchange's Science and Technology Innovation Board Issuance and Listing Review Rules .
7 - The Fifth Set of Listing Standards for Medical Device Enterprises" , which proposed to support the issuance and listing of hard-tech medical device companies that have not yet formed a certain income scale on the Science and Technology Innovation Boa.
East Asia Qianhai Securities believes that the introduction of the fifth set of listing standards on the Science and Technology Innovation Board is of great significance to the development of China's pharmaceutical industry, lowering the standards for listing companies and enhancing the inclusiveness of "hard technology" compani.
The agency said that the innovative medical device industry itself has the characteristics of high investment in research and development in the early sta.
The introduction of this standard allows companies that do not have profitable innovative drug development to go public, allowing such companies to broaden financing channels, which will help promote the development of the domestic medical device indust.
developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to the statistics of InvestGO, in the first half of 2022, there were 583 investment and financing events in the primary market, a year-on-year decrease of 47%; 30 IPO events, a year-on-year decrease of 45%; and 19 secondary market refinancing events, a year-on-year decrease of 5
However, innovative drugs and medical devices are still favored by capital, with over 300 investment and financing events in the first half of the ye.
Among them, there are 161 cases in the field of innovative drugs and 150 cases in medical devic.
In the field of innovative drugs, 34 of the 161 financing events focused on cell therapy, of which 14 were over RMB 100 milli.
In addition, there were 26 financing events in gene therapy, of which 10 were over RMB 100 milli.
It can be seen that cell therapy and gene therapy are hot tracks for innovative dru.
It is understood that cell therapy refers to the use of patient's autologous or allogeneic adult cells or stem cells, which are processed by a series of bioengineering techniques such as acquisition, isolation, culture expansion, and screening, and then returned to the patient's bo.
, Organ repair treatme.
It has great application potential in the treatment of cancer, autoimmune diseases, cardiovascular diseases and other major diseas.
In recent years, due to the resonance of multiple factors such as favorable policies and capital overweight, the cell therapy market has continued to gr.
According to Frost & Sullivan, China's cell therapy market space will increase from 3 billion yuan in 2021 to 54 billion yuan in 2030, with an average annual growth rate of 5Gene therapy is a new generation of precision therapy, which can provide new treatment concepts and means for tumors, rare diseases, chronic diseases and other intractable diseas.
As early as March 24, KPMG's "One Time Curing" Gene Therapy report pointed out that under the background that cell and gene therapy has become one of the eye-catching emerging fields in the global biotechnology field, the field of gene therapy continues to receive investo.
and large investments in biopharmaceutical compani.
Another data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from US$22 billion to US$19 billion, with an average annual compound growth rate of nearly 4
Medical devices have also attracted much attention from capit.
Among the 150 financing events in this field in the first half of the year, the average single transaction amounted to 99 million yuan, an increase of 19% over last ye.
In recent years, with the strong downstream demand, the domestic medical device industry has developed rapidly, and domestic substitution has accelerated, and the market scale has continued to expa.
A research report shows that since 2013, the market scale of China's medical device industry has continued to expa.
It is estimated that by 2022, the size of China's medical device market will reach 1,259 billion yuan, and in 2025, it will reach 1,844 billion yu.
At present, the policy side is also continuing to support the innovative development of the medical device indust.
For example, in June this year, the Shanghai Stock Exchange issued and implemented the "Guidelines for the Application of the Shanghai Stock Exchange's Science and Technology Innovation Board Issuance and Listing Review Rules .
7 - The Fifth Set of Listing Standards for Medical Device Enterprises" , which proposed to support the issuance and listing of hard-tech medical device companies that have not yet formed a certain income scale on the Science and Technology Innovation Boa.
East Asia Qianhai Securities believes that the introduction of the fifth set of listing standards on the Science and Technology Innovation Board is of great significance to the development of China's pharmaceutical industry, lowering the standards for listing companies and enhancing the inclusiveness of "hard technology" compani.
The agency said that the innovative medical device industry itself has the characteristics of high investment in research and development in the early sta.
The introduction of this standard allows companies that do not have profitable innovative drug development to go public, allowing such companies to broaden financing channels, which will help promote the development of the domestic medical device indust.
developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
